U.S. biopharmaceutical company Rivus Pharmaceuticals, Inc. has secured $35 million in its Series A financing round.

The round was co-led by California-based healthcare venture capital firm Longitude Capital and Medicxi and RxCapital also joined the round.

Rivus will use the new capital to advance a pipeline of complementary medical association therapies to treat a range of metabolic conditions.

More so, the conditions include type 2 diabetes, severe hypertriglyceridemia, non-alcoholic steatohepatitis, as well as cardiovascular diseases.